Anti-Tumor Necrosis Factor Monoclonal Antibody Treatment for Chronic Behcet's Disease: 3 Cases
Journal of the Korean Ophthalmological Society
;
: 1405-1410, 2005.
Article
in Korean
| WPRIM
| ID: wpr-25009
ABSTRACT
PURPOSE:
Despite intensive, chronic immunosuppressive therapy, permanent loss of vision resulting from relapsing ocular inflammation occurs frequently in patients with Behcet's disease. Since tumor necrosis factor (TNF) might have an important pathogenetic role in Behcet's disease, monoclonal anti-TNF antibody treatmant has introduced for chronic Behcet's disease. We report three cases of chronic Behcet's disease that were treated by monoclonal anti-TNF antibody.METHODS:
We describe the use of the anti-TNF monoclonal antibody, infliximab (Remicade(R), Schering Plough), in three patients with Behcet's disease who exhibited a severe ocular involvement refractory to standard treatment.RESULTS:
Remission of ocular inflammation was evident within the first 24~48 hours, and no relapse occurred during a 5~12 month follow up. No side effects were noted.CONCLUSIONS:
We suggest that anti-TNF monoclonal antibody (infliximab) is a rapid and effective new therapy for sight-threatening ocular inflammation in Behcet's disease.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Recurrence
/
Follow-Up Studies
/
Tumor Necrosis Factor-alpha
/
Infliximab
/
Inflammation
/
Necrosis
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2005
Type:
Article
Similar
MEDLINE
...
LILACS
LIS